Volume 121, Issue 6 , Pages 1379-1384.e1, June 2008
Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women
Background
Uncontrolled maternal asthma during pregnancy has been hypothesized as a cause of congenital malformation, but literature is scare on this topic.
Objective
The aim of this study was to investigate whether asthmatic women who had an exacerbation during the first trimester of pregnancy were more at risk of having a baby with a congenital malformation.
Methods
From the linkage of 3 Canadian administrative databases, we reconstructed a cohort of 4344 pregnancies of asthmatic women. Asthma exacerbations were assessed during the first trimester of pregnancy and were defined as a filled prescription for oral corticosteroids, an emergency department visit, or a hospitalization for asthma. Congenital malformations were assessed at birth and during the first year of life of the newborn by using diagnoses recorded in the databases. Generalized estimating equation models were used to estimate adjusted odds ratios of congenital malformations in association with asthma exacerbations.
Results
In the cohort we identified 398 (9.2%) babies with at least 1 malformation and 261 (6.0%) with a major malformation. The crude prevalences of malformations were 12.8% and 8.9%, respectively, for women who had and those who did not have an exacerbation. The adjusted odds ratio for all malformations was 1.48 (95% CI, 1.04-2.09) when comparing women who had and those who did not have an exacerbation. The corresponding figures were 1.32 (95% CI, 0.86-2.04) for major malformations.
Conclusion
Asthma exacerbations during the first trimester of pregnancy were found to significantly increase the risk of a congenital malformation.
Key words: Asthma, pregnancy, exacerbation, congenital malformations, cohort study, administrative health databases
Abbreviations used: ED, Emergency department, GEE, Generalized estimating equation, ICD-9, International Classification of Diseases–9th Revision, ISQ, Institut de la statistique du Québec, OR, Odds ratio, RAMQ, Régie de l'assurance-maladie du Québec
L. Blais is the recipient of a Salary Award from the Fonds de la recherché en santé du Québec (FRSQ) and is the Endowment Pharmaceutical Chair AstraZeneca in Respiratory Health. This study was funded through grants received from the Fonds de la recherche en santé du Québec (FRSQ), the Canadian Institutes of Health Research (CIHR), and the Canadian Foundation for Innovation.
Disclosure of potential conflict of interest: L. Blais has received research support from AstraZeneca, Amgen, and GlaxoSmithKline. A. Forget has declared that she has no conflict of interest.
PII: S0091-6749(08)00521-6
doi:10.1016/j.jaci.2008.02.038
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 121, Issue 6 , Pages 1379-1384.e1, June 2008
